Data Foundry

Medical device recalls 2024

BD BBL Sensi Disc Rifampin- 5 ug — Class II medical device recall Z-1038-2024

Ongoing recall by Becton Dickinson & Co., reported 2024-02-14, distributed nationwide. There is a possibility of reproducibility, accuracy, and/or QC failures in antibiotic susceptibility testing (

Recall numberZ-1038-2024
Product typeMedical device
ClassificationClass II
StatusOngoing
Voluntary or mandatedVoluntary
Recalling firmBecton Dickinson & Co., Sparks, MD, United States
Recall initiated2024-01-08
Classified2024-02-08
Reported by FDA2024-02-14
DistributedNationwide (US)
Quantity2,363,168 units
UPC / GTIN / UDI-DI00382902315414, 30382902315446
Lot numbers0343413, 1032232, 1088790, 1116055, 1148547, 1211489, 1278110, 1334479, 2004554, 2025125, 2056466, 2090443, 2242510, 2339407, 3030278, 3158059, 3214931
Model numbers231541

Product

BD BBL Sensi Disc Rifampin- 5 ug, used for semi-quantitative in vitro susceptibility testing. Catalog Number 231541 and 231544¿

Reason for recall

There is a possibility of reproducibility, accuracy, and/or QC failures in antibiotic susceptibility testing (AST) for H. influenzae. This may cause product discard, delayed results, or additional adverse diagnostic outcomes, such as a delay in diagnosis, the selection of inappropriate antibiotics, or extended duration of antibiotic exposure and the treatment process.

Machine access

This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/Z-1038-2024. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.

Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-09-26. Not affiliated with or endorsed by FDA. Not medical or legal advice.